Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could two blood thinners save more hearts after bypass?

NCT ID NCT03560310

Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study compares two blood thinners (ticagrelor plus aspirin) against aspirin alone after coronary artery bypass grafting (CABG) in people who recently had a heart attack or unstable angina. Over 2,200 participants are being followed for 12 months to see if the dual therapy reduces major heart problems like death, heart attack, or stroke. The goal is to find the best way to protect patients after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ticagrelor and aspirin (acetylsalicylic acid)
What this could lead to
If it works, this could lead to a better standard treatment after heart bypass surgery to prevent future heart attacks, strokes, or death.
What could go wrong
This is a late-stage trial, but adding a second blood thinner increases bleeding risk. The benefit may be small or not outweigh the risks for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

2,201 people

The number who actually took part.

Started

Jun 2018

Expected to finish

Feb 2035

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent 2. Age ≥18 years 3. Has undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery Exclusion Criteria: 1. Previously enrolled in this study (i.e. patient now at repeat encounter) 2. Concomitant surgical procedure other than CABG 3. Anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux) 4. Discharge from the operating hospital to an ICU at another hospital 5. Pregnancy or lactation 6. Known intolerance or contraindication to ticagrelor or ASA 7. Any disorder that may interfere with drug absorption 8. Any condition other than coronary artery disease with a life expectancy \<12 months 9. Known chronic liver disease, renal disease requiring dialysis or bleeding disorder 10. Atrioventricular block II and III in patients without pacemaker 11. Any other indication for dual antiplatelet therapy, i.e. recent stent implantation 12. Debilitating stroke within 90 days before inclusion 13. Previous intracranial bleeding 14. Treatment with immunosuppressants (e.g. cyclosporine and tacrolimus) 15. Treatment with strong CYP3A4-inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir) 16. Any condition that in the opinion of the investigator may interfere with adherence to trial protocol 17. Participation in any other clinical trial evaluating investigational products at the time for enrollment in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Blekinge Hospital

    Karlskrona, Sweden

  • Haukeland University Hospital

    Trondheim, Norway

  • Helsinki University Hospital

    Helsinki, Finland

  • Karolinska University Hospital

    Stockholm, Sweden

  • Kuopio University Hospital

    Kuopio, Finland

  • Landspítali University Hospital

    Reykjavik, Iceland

  • Linköping University Hospital

    Linköping, Sweden

  • Odense University Hospital

    Odense, Denmark

  • Oslo University Hospital

    Oslo, Norway

  • Oulu University Hospital

    Oulu, Finland

  • Rigshospitalet

    Copenhagen, Denmark

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Skåne University Hospital

    Lund, Sweden

  • St. Olavs hospital, University Hospital

    Bergen, Norway

  • Tampere University Hospital

    Tampere, Finland

  • Turku University Hospital

    Turku, Finland

  • University Hospital of North Norway

    Tromsø, Norway

  • University Hospital of Umeå

    Umeå, Sweden

  • Uppsala University Hospital

    Uppsala, Sweden

  • Örebro University Hospital

    Örebro, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.